Roles of pleiotrophin in tumor growth and angiogenesis

European Cytokine Network

Volumn 20, Issue 4, 2009, Pages 180-190

  Papadimitriou, Evangelia ^a   Mikelis, Constantinos ^a   Lampropoulou, Evgenia ^a   Koutsioumpa, Marina ^a   Theochari, Katerina ^a   Tsirmoula, Sotiria ^a   Theodoropoulou, Christina ^a   Lamprou, Margarita ^a   Sfaelou, Evanthia ^a   Vourtsis, Dionyssios ^a   Boudouris, Panagiotis ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Angiogenesis; Cancer; Endothelial cells; Integrins; Pleiotrophin; Receptor protein tyrosine phosphatase

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CHONDROITIN SULFATE; GAMMA SECRETASE; GELATINASE B; PLASMIN; PLEIOTROPHIN; PRESENILIN; PROTEIN TYROSINE PHOSPHATASE; PROTEOGLYCAN; RECEPTOR PROTEIN TYROSINE PHOSPHATASE BETA; RECEPTOR PROTEIN TYROSINE PHOSPHATASE ZETA; SYNDECAN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; VASCULOTROPIN; VERSICAN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BINDING SITE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER DIAGNOSIS; DIMERIZATION; GENE STRUCTURE; HUMAN; IN VITRO STUDY; LIGAND BINDING; MOLECULAR BIOLOGY; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CARRIER PROTEINS; CELL PROLIFERATION; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC;

EID: 72249089091     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2009.0172     Document Type: Review

References (186)

1. Merenmies J, Rauvala H. Molecular cloning of the 18kDa growth-associated protein of developing brain. J Biol Chem 1990; 265: 16721. (Pubitemid 20334195)
2. Hampton BS, Marshak DR, Burgess DS. Structural and functional characterization of full-length heparin-binding growth associated molecule. Mol Biol Cell 1992; 3: 85.
3. Laaroubi K, Vacherot F, Delbe J, Caruelle D, Barritault D, Courty J. Biochemical and mitogenic properties of the heparin-binding growth factor HARP. Prog Growth Factor Res 1995; 6: 25. (Pubitemid 2617291)
4. Milner PG, Li YS, Hoffman RM, Kodner CM, Siegel NR, Deuel TF. A Novel 17 kD Heparin-Binding Growth Factor (HBGF-8) in Bovine Uterus: Purification and N-Terminal Amino Acid Sequence. Biochem Biophys Res Commun 1989; 165: 1096.
5. Rauvala H. An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J 1989; 8: 2933. (Pubitemid 19274995)
6. Kovesdi I, Fairhurst JL, Kretschmer PJ, Böhlen P. Heparin-binding neurotrophic factor (HBNF) and MK, members of a new family of homologous, developmentally regulated proteins. Biochem and Biophys Res Commun 1990; 172: 850. (Pubitemid 20384501)
7. Böhlen P, Müller T, Gautschi-Sova P, et al. Isolation from bovine brain and structural characterization of HBNF, a heparin-binding neurotrophic factor. Growth Factors 1991; 4: 97.
8. Tezuka K, Takeshita S, Hakeda Y, Kumegawa M, Kikuno R, Hashimoto-Gotoh T. Isolation of mouse and human cDNA clones encoding a protein expressed specifically in osteoblasts and brain tissues. Biochem Biophys Res Commun 1990; 173: 246.
9. Kretschmer PJ, Fairhurst JL, Decker MM, et al. Cloning, characterization and developmental regulation of two members of a novel human gene family of neurite outgrowth-promoting proteins. Growth Factors 1991; 5: 99.
10. Tsutsui J, Uehara K, Kadomatsu K, Matsubara S, Muramatsu T. A new family of heparin-binding factors: strong conservation of midkine (MK) sequences between the human and the mouse. Biochem Biophys Res Commun 1991; 176: 792.
11. Englund C, Birve A, Falileeva L, Grabbe C, Palmer RH. Miple1 and miple2 encode a family of MK/PTN homologues in Drosophila melanogaster. Dev Genes Evol 2005; 216: 10. (Pubitemid 43124304)
12. Kuo MD, Oda Y, Huang JS, Huang SS. Amino acid sequence and characterization of a heparin binding neurite-promoting factor (p18) from bovine brain. J Biol Chem 1990; 265: 18749. (Pubitemid 20378521)
13. Li YS, Milner PG, Chauhan AK, et al. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science 1990; 250: 1690.
14. Kilpelainen I, Kaksonen M, Kinnunen T, et al. Heparin-binding growth-associated molecule contains two heparin-binding betasheet domains that are homologous to the thrombospondin type I repeat. J Biol Chem 2000; 275: 13564. (Pubitemid 30257423)
15. Fabri L, Nice EC, Ward LD, Maruta H, Burgess AW, Simpson RG. Characterization of bovine heparin-binding neurotrophic factor (HBNF): assignment of disulfide bonds. Biochem Int 1992; 28: 1.
16. Inui T, Nakao M, Nishio H, et al. Solution synthesis and biological activity of human pleiotrophin, a novel heparin-binding neurotrophic factor consisting of 136 amino acid residues with five disulfide bonds. J Pept Res 2000; 55: 384. (Pubitemid 30324174)
17. Ori A, Free P, Courty J, Wilkinson MC, Fernig DG. Identification of heparin binding sites in proteins by selective labelling. Mol Cell Proteomics 2009 (Epub ahead of print).
18. Li YS, Hoffman RM, Le Beauin MM, et al. Characterization of the human pleiotrophin gene. J Biol Chem 1992; 267: 26011.
19. Kretschmer PJ, Fairhurst JL, Hulmes JD, Popjes ML, Böhlen P, Kovesdi I. Genomic structure of the human HBNF gene and characterization of the HBNF variant protein as a splice mutant. Biochem Biophys Res Commun 1993; 192: 420. (Pubitemid 23227340)
20. Lai S, Czubayko F, Riegel AT, Wellstein A. Structure of the human heparin-binding growth factor gene pleiotrophin. Biochem Biophys Res Commun 1992; 187: 1113.
21. Lai S, Schulte AM, Wellstein A, Riegel AT. An additional 5′- upstream exon exists in the human pleiotrophin-encoding gene. Gene 1995; 153: 301.
22. Lee KE, Nam S, Cho EA, et al. Identification of direct regulatory targets of the transcription factor Sox10 based on function and conservation. BMC Genomics 2008; 9: 408.
23. Liedert A, Kassem M, Claes L, Ignatius A. Mechanosensitive promoter region in the human HB-GAM gene. Biochem Biophys Res Commun 2009; 387: 289.
24. Pufe T, Bartscher M, Petersen W, Tillmann B, Mentlein R. Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis. Arthritis Rheum 2003; 48: 660. (Pubitemid 36302001)
25. Pufe T, Grothy G, Goldring MB, Tillmann B, Mentlein R. Effects of pleiotrophin, a heparin-binding growth factor, on human primary and immortalized chondrocytes. Osteoarthritis Cartilage 2007; 15: 155. (Pubitemid 46132101)
26. Li G, Bunn JR, Mushipe MT, He Q, Chen X. Effects of pleiotrophin (PTN) over-expression on mouse long bone development, fracture healing and bone repair. Calcif Tissue Int 2005; 76: 299. (Pubitemid 40991401)
27. Ezquerra L, Alguacil LF, Nguyen T, Deuel TF, Santiago IS, Herradon G. Different pattern of pleiotrophin and midkine expression in neuropathic pain: Correlation between changes in pleiotrophin gene expression and rat strain differences in neuropathic pain. Growth Factors 2008; 26: 44.
28. Roger J, Brajeul V, Thomasseau S, et al. Involvement of Pleiotrophin in CNTF-mediated differentiation of the late retinal progenitor cells. Dev Biol 2006; 298: 527. (Pubitemid 44441190)
29. Hatziapostolou M, Polytarchou C, Katsoris P, Courty J, Papadimitriou E. Heparin affin regulatory peptide/ pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. J Biol Chem 2006; 281: 32217. (Pubitemid 46036776)
30. Mitsiadis TA, Caton J, De Bari C, Bluteau G. The large functional spectrum of the heparin-binding cytokines MK and HB-GAM in continuously growing organs: the rodent incisor as a model. Dev Biol 2008; 320: 256.
31. Li YS, Gurrieri M, Deuel TF. Pleiotrophin gene expression is highly restricted and is regulated by platelet-derived growth factor. Biochem Biophys Res Commun 1992; 184: 427.
32. Antoine M, Tag CG, Wirz W, et al. Upregulation of pleiotrophin expression in rat hepatic stellate cells by PDGF and hypoxia: Implications for its role in experimental biliary liver fibrogenesis. Biochem Biophys Res Commun 2005; 337: 1153. (Pubitemid 41505246)
33. Mourlevat S, Debeir T, Ferrario JE, et al. Pleiotrophin mediates the neurotrophic effect of cyclic AMP on dopaminergic neurons: Analysis of suppression-subtracted cDNA libraries and confirmation in vitro. Exp Neurol 2005; 194: 243. (Pubitemid 40719759)
34. Poimenidi E, Hatziapostolou M, Papadimitriou E. Serum stimulates Pleiotrophin gene expression in an AP-1-dependent manner in human endothelial and glioblastoma cells. Anticancer Res 2009; 29: 349.
35. Polytarchou C, Hatziapostolou M, Papadimitriou E. Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and upregulation of the heparin affin regulatory peptide gene. J Biol Chem 2005; 280: 40428. (Pubitemid 41780529)
36. Polytarchou C, Hatziapostolou M, Poimenidi E, et al. Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase beta/zeta. Int J Cancer 2009; 124: 1785.
37. Brunet-de Carvalho N, Raulais D, Rauvala H, Souttou B, Vigny M. HB-GAM/Pleiotrophin and midkine are differently expressed and distributed during retinoic acid-induced neural differentiation of P19 cells. Growth Factors 2003; 21: 139. (Pubitemid 37541138)
38. Chen H, Rubin E, Zhang H, et al. Identification of transcriptional targets of HOXA5. J Biol Chem 2005; 280: 19373.
39. Li G, Hu Y, Huo Y, et al. PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin. J Biol Chem 2006; 281: 10663. (Pubitemid 43855487)
40. Rauvala H, Vanhala A, Castren E, et al. Expression of HB-GAM (heparin-binding growth-associated molecules) in the pathways of developing axonal processes in vivo and neurite outgrowth in vitro induced by HB-GAM. Brain Res Dev Brain Res 1994; 79: 157. (Pubitemid 24196037)
41. Takeda A, Onodera H, Sugimoto A, et al. Induction of heparin-binding growth-associated molecule expression in reactive astrocytes following hippocampal neuronal injury. Neuroscience 1995; 68: 57.
42. Silos-Santiago I, Yeh HJ, Gurrieri MA, et al. Localization of pleiotrophin and its mRNA in subpopulations of neurons and their corresponding axonal tracts suggests important roles in neural-glial interactions during development and in maturity. J Neurobiol 1996; 31: 283. (Pubitemid 26362225)
43. Yeh HJ, He YY, Xu J, Hsu CY, Deuel TF. Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury. J Neurosci 1998; 18: 3699. (Pubitemid 28225677)
44. Pavlov I, Voikar V, Kaksonen M, et al. Role of heparin-binding growth-associated molecule (HB-GAM) in hippocampal LTP and spatial learning revealed by studies on overexpressing and knockout mice. Mol Cell Neurosci 2002; 20: 330. (Pubitemid 34762141)
45. Hida H, Jung CG, Wu CZ, et al. Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro. Eur J Neurosci 2003; 17: 2127. (Pubitemid 36713973)
46. Hida H, Masuda T, Sato T, Kim TS, Misumi S, Nishino H. Pleiotrophin promotes functional recovery after neural transplantation in rats. Neuroreport 2007; 18: 179. (Pubitemid 46263312)
47. Hienola A, Pekkanen M, Raulo E, Vanttola P, Rauvala H. HBGAM inhibits proliferation and enhances differentiation of neural stem cells. Mol Cell Neurosci 2004; 26: 75. (Pubitemid 38581024)
48. Jung CG, Hida H, Nakahira K, Ikenaka K, Kim HJ, Nishino H. Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells. FASEB J 2004; 18: 1237. (Pubitemid 39561562)
49. Blondet B, Carpentier G, Lafdil F, Courty J. Pleiotrophin cellular localization in nerve regeneration after peripheral nerve injury. J Histochem Cytochem 2005; 53: 971. (Pubitemid 41045420)
50. Gramage E, Alguacil LF, Herradon G. Pleiotrophin prevents cocaine-induced toxicity in vitro. Eur J Pharmacol 2008; 595: 35.
51. del Olmo N, Gramage E, Alguacil LF, Pérez-Pinera P, Deuel TF, Herradón G. Pleiotrophin inhibits hippocampal long-term potentiation: a role of pleiotrophin in learning and memory. Growth Factors 2009; 27: 189.
52. Wisniewski T, Lalowski M, Baumann M, et al. HB-GAM is a cytokine present in Alzheimer's and Down's syndrome lesions. Neuroreport 1996; 7: 667. (Pubitemid 26105055)
53. Vazin T, Becker KG, Chen J, et al. A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells. PLoS One 2009; 4: e6606.
54. Peng HB, Ali AA, Dai Z, Daggett DF, Raulo E, Rauvala H. The role of heparin-binding growth-associated molecule (HB-GAM) in the postsynaptic induction in cultured muscle cells. J Neurosci 1995; 5: 3027.
55. Caruelle D, Mazouzi Z, Husmann I, et al. Upregulation of HARP during in vitro myogenesis and rat soleus muscle regeneration. J Muscle Res Cell Motil 2004; 25: 45. (Pubitemid 39023442)
56. Milhiet PE, Vacherot F, Caruelle JP, Barritault D, Caruelle D, Courty J. Upregulation of the angiogenic factor heparin affin regulatory peptide by progesterone in rat uterus. J Endocrinol 1998; 158: 389. (Pubitemid 28407546)
57. Mitsiadis TA, Salmivirta M, Muramatsu T, et al. Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis. Development 1995; 121: 37.
58. Chen HW, Yu SL, Chen WJ, et al. Dynamic changes of gene expression profiles during postnatal development of the heart in mice. Heart 2004; 90: 927.
59. Asakura M, Kitakaze M. Global gene expression profiling in the failing myocardium. Circ J 2009; 73: 1568.
60. Li J, Wei H, Chesley A, et al. The pro-angiogenic cytokine pleiotrophin potentiates cardiomyocyte apoptosis through inhibition of endogenous AKT/PKB activity. J Biol Chem 2007; 282: 34984. (Pubitemid 350232463)
61. Asahina K, Sato H, Yamasaki C, et al. Pleiotrophin/Heparin- Binding Growth-Associated Molecule as a mitogen of rat hepatocytes and its role in regeneration and development of liver. Am J Pathol 2002; 160: 2191. (Pubitemid 34663410)
62. Sakurai H, Bush KT, Nigam SK. Identification of pleiotrophin as a mesenchymal factor involved in ureteric bud branching morphogenesis. Development 2001; 128: 3283. (Pubitemid 32910381)
63. Weng T, Gao L, Bhaskaran M, et al. Pleiotrophin regulates lung epithelial cell proliferation and differentiation during fetal lung development via {beta}-catenin and Dlk1. J Biol Chem 2009 (Epub ahead of print).
64. Zou P, Muramatsu H, Sone M, Hayashi H, Nakashima T, Muramatsu T. Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of beta-tectorin gene and in auditory response. Lab Invest 2006; 86: 645. (Pubitemid 43901662)
65. Muramatsu H, Zou P, Kurosawa N, et al. Female infertility in mice deficient in midkine and pleiotrophin, which form a distinct family of growth factors. Genes Cells 2006; 11: 1405. (Pubitemid 44774203)
66. Ledoux D, Caruelle D, Sabourin JC, et al. Cellular distribution of the angiogenic factor heparin affin regulatory peptide (HARP) mRNA and protein in the human mammary gland. J Histochem Cytochem 1997; 45: 1239. (Pubitemid 27392331)
67. Kouros-Mehr H, Werb Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn 2006; 235: 3404. (Pubitemid 44888206)
68. Chung HW, Wen Y, Choi EA, Hao-Li et al. Pleiotrophin (PTN) and midkine (MK) mRNA expression in eutopic and ectopic endometrium in advanced stage endometriosis. Mol Hum Reprod 2002; 8: 350. (Pubitemid 34303243)
69. Qian A, Meals RA, Rajfer J, Gonzales-Cadavid NF. Comparison of gene expression profiles between Peuronie's disease and Dupuytren's contracture. Urology 2004; 64: 99.
70. Vernet D, Nolazco G, Cantini L, et al. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for Peyronie disease. Biol Reprod 2005; 73: 1199. (Pubitemid 41698610)
71. Zhang N, Yeh HJ, Zhong R, Li YS, Deuel TF. A dominant-negative pleiotrophin mutant introduced by homologous recombination leads to germ-cell apoptosis in male mice. Proc Natl Acad Sci U S A 1999; 96: 6734. (Pubitemid 29274952)
72. Zhou H-Y, Ohnuma Y, Takita H, Fujisawa R, Mizuno M, Kuboki Y. Effects of a bone lysine-rich 18KDa protein on osteoblast-like MC3T3-E1 cells. Biochem Biophys Res Commun 1992; 186: 1288. (Pubitemid 23189463)
73. Imai S, Kaksonen M, Raulo E, et al. Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM). J Cell Biol 1998; 143: 1113. (Pubitemid 28547408)
74. Yang X, Tare RS, Partridge KA, et al. Induction of human osteoprogenitor chemotaxis, proliferation, differentiation, and bone formation by osteoblast stimulating factor-1/pleiotrophin: osteo-conductive biomimetic scaffolds for tissue engineering. J Bone Miner Res 2003; 18: 47. (Pubitemid 36008339)
75. Petersen W, Rafii M. Immunolocalization of the angiogenetic factor pleiotrophin (PTN) in the growth plate of mice. Arch Orthop Trauma Surg 2001; 121: 414. (Pubitemid 32684981)
76. Sato Y, Takita H, Ohata N, Tamura M, Kuboki Y. Pleiotrophin regulates bone morphogenetic protein (bmp)-induced ectopic osteogenesis. J Biochem 2002; 131: 877. (Pubitemid 34717593)
77. Xing W, Baylink D, Kesavan C, et al. Global gene expression analysis in the bones reveals involvement of several novel genes and pathways in mediating an anabolic response of mechanical loading in mice. J Cell Biochem 2005; 96: 1049. (Pubitemid 41688728)
78. Tare RS, Oreffo ROC, Sato K, Rauvala H, Clarke NMP, Roach HI. Effects of targeted overexpression of pleiotrophin on postnatal bone development. Biochem Biophys Res Commun 2002; 298: 324. (Pubitemid 35333708)
79. Lehmann W, Schinke T, Schilling AF, et al. Absence of mouse pleiotrophin does not affect bone formation in vivo. Bone 2004; 35: 1247. (Pubitemid 40260390)
80. Imai S, Heino TJ, Hienola A, et al. Osteocyte-derived HB-GAM (pleiotrophin) is associated with bone formation and mechanical loading. Bone 2009; 44: 785.
81. Dreyfus J, Brunet-de Carvalho N, Duprez D, Raulais D, Vigny M. HB-GAM/pleiotrophin: localization of mRNA and protein in the chicken developing leg. Int J Dev Biol 1998; 42: 189. (Pubitemid 28109380)
82. Neame PJ, Young CN, Brock CW, et al. Pleiotrophin is an abundant protein in dissociative extracts of bovine fetal epiphyseal cartilage and nasal cartilage from newborns. J Orthop Res 1993; 11: 479.
83. Tapp H, Hernandez DJ, Neame PJ, Koob TJ. Pleiotrophin inhibits chondrocyte proliferation and stimulates proteoglycan synthesis in mature bovine cartilage. Matrix Biol 1999; 18: 543.
84. Pufe T, Bartscher M, Petersen W, Tillmann B, Mentlein R. Pleiotrophin, an embryonic differentiation and growth factor, is expressed in osteoarthritis. Osteoarthritis Cartilage 2003; 11: 260. (Pubitemid 36410878)
85. Sanchez C, Deberg MA, Piccardi N, Msika P, Reginster JY, Henrotin YE. Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2005; 13: 988. (Pubitemid 41536131)
86. Lupu R, Wellstein A, Sheridan J, et al. Purification and characterization of a novel growth factor from human breast cancer cells. Biochemistry 1992; 31: 7330.
87. Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem 1992; 267: 25889. (Pubitemid 23013992)
88. Wellstein A, Fang WJ, Khatri A, et al. A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J Biol Chem 1992; 267: 2582.
89. Zhang N, Zhong R, Wang ZY, Deuel TF. Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant. J Biol Chem 1997; 272: 16733. (Pubitemid 27289766)
90. Vacherot F, Caruelle D, Chopin D, et al. Involvement of heparin affin regulatory peptide in human prostate cancer. Prostate 1999; 38: 126. (Pubitemid 29052951)
91. Hatziapostolou M, Delbe J, Katsoris P, Polytarchou C, Courty J, Papadimitriou E. Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity. Prostate 2005; 65: 151. (Pubitemid 41362282)
92. Jager R, Noll K, Havemann K, et al. Differential expression and biological activity of the Heparin-Binding Growth-Associated Molecule (HB-GAM) in lung cancer cell lines. Int J Cancer 1997; 73: 537. (Pubitemid 28005318)
93. Schulte AM, Lai S, Kurtz A, Czubayko F, Riegel AT, Wellstein A. Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus. Proc Natl Acad Sci U S A 1996; 93: 14759. (Pubitemid 26419042)
94. Czubayko F, Schulte AM, Berchem GJ, Wellstein A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci U S A 1996; 93: 14753. (Pubitemid 26419041)
95. Mentlein R, Held-Feindt J. Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J Neurochem 2002; 83: 747. (Pubitemid 35316024)
96. Zhang L, Mabuchi T, Satoh E, Maeda S, Nukui H, Naganuma H. Overexpression of heparin-binding growth-associated molecule in malignant glioma cells. Neurol Med Chir (Tokyo) 2004; 44: 637. (Pubitemid 40040644)
97. Lu KV, Jong KA, Kim GY, et al. Differential induction of glioblastoma migration and growth by two forms of Pleiotrophin. J Biol Chem 2005; 280: 26953.
98. Grzelinski M, Bader N, Czubayko F, Aigner F. Ribozymetargeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int J Cancer 2005; 117: 942. (Pubitemid 41688568)
99. Weber D, Klomp HJ, Czubayko F, Wellstein A, Juhl H. Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. Cancer Res 2000; 60: 5284. (Pubitemid 30739790)
100. Chen H, Gordon M, Campbell R, et al. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood 2007; 110: 287. (Pubitemid 47026846)
101. Tong Y, Mentlein R, Buhl R, et al. Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas. J Neurochem 2007; 100: 1097. (Pubitemid 46213932)
102. Chang Y, Berenson J, Wang Z, Deuel TF. Dominant negative pleiotrophin induces tetraploidy and aneuploidy in U87MG human glioblastoma cells. Biochem Biophys Res Commun 2006; 351: 336. (Pubitemid 44666694)
103. Perez-Pinera P, Alcantara S, Dimitrov T, Vega JA, Deuel TF. Pleiotrophin disrupts calcium-dependent homophilic cell-cell adhesion and initiates an epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 2006; 103: 17795. (Pubitemid 44852239)
104. Park TJ, Jeong BR, Tateno C, et al. Pleiotrophin inhibits transforming growth factor beta1-induced apoptosis in hepatoma cell lines. Mol Carcinog 2008; 47: 784.
105. Chang Y, Zuka M, Perez-Pinera P, et al. Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment. Proc Natl Acad Sci U S A 2007; 104: 10888. (Pubitemid 47175196)
106. Yamakawa T, Kurosawa N, Kadomatsu K, et al. Levels of expression of pleiotrophin and protein tyrosine phosphatase zeta are decreased in human colorectal cancers. Cancer Lett 1999; 135: 91. (Pubitemid 29069070)
107. Corbley MJ. Transformation by Ras suppresses expression of the neurotrophic growth factor pleiotrophin. J Biol Chem 1997; 272: 24696.
108. Merenmies J. Cell density-dependent expression of heparin-binding growth-associated molecule (HB-GAM, p18) and its down-regulation by fibroblast growth factors. FEBS Letters 1992; 307: 297.
109. Papadimitriou E, Polykratis A, Hatziapostolou M, Parthymou A, Polytarchou C, Mikelis C. Heparin affin regulatory peptide: a new target for tumour therapy? Curr Cancer Drug Targets 2004; 4: 471.
110. Calvet L, Geoerger B, Regairaz M, et al. Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan. Oncogene 2006; 25: 3150. (Pubitemid 43881556)
111. Parthymou A, Lampropoulou E, Mikelis C, Drosou G, Papadimitriou E. Heparin affin regulatory peptide/pleiotrophin negatively affects diverse biological activities in C6 glioma cells. Eur J Cell Biol 2008; 87: 17. (Pubitemid 350246273)
112. Mikelis C, Sfaelou E, Koutsioumpa M, Kieffer N, Papadimitriou E. Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta. FASEB J 2009; 23: 1459.
113. Papadimitriou E, Heroult M, Courty J, Polykratis A, Stergiou C, Katsoris P. Endothelial cell proliferation induced by HARP: Implication of N or C terminal peptides. Biochem Biophys Res Commun 2000; 274: 242. (Pubitemid 30496786)
114. Papadimitriou E, Polykratis A, Courty J, Koolwijk P, Heroult M, Katsoris P. HARP Induces Angiogenesis in Vivo and in Vitro: Implication of N or C terminal peptides. Biochem Biophys Res Commun 2001; 282: 306. (Pubitemid 32924380)
115. Souttou B, Raulais D, Vigny M. Pleiotrophin induces angiogenesis: involvement of the phosphoinositide-3 kinase but not the nitric oxide synthase pathways. J Cell Physiol 2001; 187: 59. (Pubitemid 32195245)
116. Polykratis A, Katsoris P, Courty J, Papadimitriou E. Characterization of heparin affin regulatory peptide signaling in human endothelial cells. J Biol Chem 2005; 280: 22454. (Pubitemid 40827901)
117. Heiss C, Wong ML, Block VI, et al. Pleiotrophin induces nitric oxide dependent migration of endothelial progenitor cells. J Cell Physiol 2008; 215: 366.
118. Magnusson PU, Dimberg A, Mellberg S, Lukinius A, Claesson- Welsh L. FGFR-1 regulates angiogenesis through cytokines interleukin-4 and pleiotrophin. Blood 2007; 110: 4214.
119. Sharifi BG, Zeng Z, Wang L, et al. Pleiotrophin induces trans-differentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: 1273. (Pubitemid 44305370)
120. Chen H, Campbell RA, Chang Y, et al. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood 2009; 113: 1992.
121. Collino F, Revelli A, Massobrio M, et al. Epithelial-mesenchymal transition of ovarian tumor cells induces an angiogenic monocyte cell population. Exp Cell Res 2009 (Epub ahead of print).
122. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell A. An Angiogenic Role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997; 57: 1814. (Pubitemid 27199678)
123. Heroult M, Bernard-Pierrot I, Delbe J, et al. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene 2004; 23: 1745. (Pubitemid 38445166)
124. Polykratis A, Delbe J, Courty J, Papadimitriou E, Katsoris P. Identification of heparin affin regulatory peptide domains with potential role on angiogenesis. Int J Biochem Cell Biol 2004; 36: 1954.
125. Kokolakis G, Mikelis C, Papadimitriou E, Courty J, Karetsou E, Katsoris P. Effect of heparin affin regulatory peptide on the expression of vascular endothelial growth factor receptors in endothelial cells. In Vivo 2006; 20: 629. (Pubitemid 44680196)
126. Chauhan AK, Li YS, Deuel TF. Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc Natl Acad Sci U S A 1993; 90: 679.
127. Zhang N, Zhong R, Perez-Pinera P, et al. Identification of the angiogenesis signaling domain in pleiotrophin defines a mechanism of the angiogenic switch. Biochem Biophys Res Commun 2006; 343: 653.
128. Grzelinski M, Urban-Klein B, Martens T, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006; 17: 751. (Pubitemid 44100720)
129. Hamma-Kourbali Y, Bernard-Pierrot I, Heroult M, et al. Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its C-thrombospondin repeat-I domain. J Cell Physiol 2008; 214: 250. (Pubitemid 350220079)
130. Bernard-Pierrot I, Delbe J, Caruelle D, Barritault D, Courty J, Milhiet PE. The lysine-rich c-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities. J Biol Chem 2001; 276: 12228. (Pubitemid 37385391)
131. Ducès A, Karaky R, Martel-Renoir D, et al. 16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development. Mol Cancer Ther 2008; 7: 2817.
132. Bernard-Pierrot I, Delbe J, Rouet V, et al. Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities. J Biol Chem 2002; 277: 32071. (Pubitemid 34969018)
133. Bermek O, Diamantopoulou Z, Polykratis A, et al. A basic peptide derived from the HARP C-terminus inhibits anchorageindependent growth of DU145 prostate cancer cells. Exp Cell Res 2007; 313: 4041. (Pubitemid 47632541)
134. Raulo E, Chernousov MA, Carey DJ, Nolo R, Rauvala H. Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). J Biol Chem 1994; 269: 12999.
135. Kinnunen T, Kaksonen M, Saarinen J, Kalkkinen N, Peng HB, Rauvala H. Cortactin-Src kinase signaling pathway is involved in N-syndecan-dependent neurite outgrowth. J Biol Chem 1998; 273: 10702. (Pubitemid 28227685)
136. Raulo E, Tumova S, Pavlov I, et al. The two thrombospondin type I repeat domains of the heparin-binding growth-associated molecule bind to heparin/heparan sulfate and regulate neurite extension and plasticity in hippocampal neurons. J Biol Chem 2005; 280: 41576. (Pubitemid 41832220)
137. Raulo E, Tumova S, Pavlov I, et al. The two thrombospondin type I repeat domains of HB-GAM display a cooperative function in N-syndecan binding and regulation of synaptic plasticity. ScientificWorldJournal 2006; 6: 406.
138. Nolo R, Kaksonen M, Raulo E, Rauvala H. Co-expression of heparin-binding growth-associated molecule (HB-GAM) and N-syndecan (syndecan-3) in developing rat brain. Neurosci Lett 1995; 19: 39.
139. Iseki K, Hagino S, Mori T, et al. Increased syndecan expression by pleiotrophin and FGF receptor- expressing astrocytes in injured brain tissue. Glia 2002; 39: 1.
140. Landgraf P, Wahle P, Pape HC, Gundelfinger ED, Kreutz MR. The Survival-promoting Peptide Y-P30 Enhances Binding of Pleiotrophin to Syndecan-2 and -3 and Supports Its Neuritogenic Activity. J Biol Chem 2008; 283: 25036.
141. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene ALK, to a nucleolar protein gene NPM, in non- Hodgkin's lymphoma. Science 1994; 263: 1281.
142. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14: 439. (Pubitemid 27087107)
143. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14: 2175.
144. Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001; 276: 16772. (Pubitemid 37411470)
145. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002; 277: 14153. (Pubitemid 34968027)
146. Bowden ET, Stoica GE, Wellstein A. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 2002; 277: 35862.
147. Stylianou DC, Auf der Maur A, Kodack DP, et al. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene 2009 (Epub ahead of print).
148. Hausser HJ, Brenner RE. Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun 2005; 333: 216.
149. Perez-Pinera P, Chang Y, Astudillo A, Mortimer J, Deuel TF. Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. Biochem Biophys Res Commun 2007; 358: 399. (Pubitemid 46755722)
150. Dirks WG, Fahnrich S, Lis Y, Becker E, Macleodand RAF, Drexler HG. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer 2002; 100: 49. (Pubitemid 34602064)
151. Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000; 156: 1711. (Pubitemid 30646709)
152. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997; 89: 1483. (Pubitemid 27097438)
153. Li X-Q, Hisaoka M, Shi DR, Zhu XZ, Hashimoto H. Expression of anaplastic lymphoma kinase in soft tissue tumors: An immunohistochemical and molecular study of 249 cases. Hum Pathol 2004; 35: 711. (Pubitemid 38881081)
154. Miyake I, Hakomori Y, Shinohara A, et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002; 21: 5823. (Pubitemid 35007232)
155. Moog-Lutz C, Degoutin J, Gouzi JY, et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005; 280: 26039. (Pubitemid 41022195)
156. Motegi A, Fujimoto J, Kotani M, Sakuraba H, Yamamoto T. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 2004; 117: 3319. (Pubitemid 39139916)
157. Mourali J, Bénard A, Lourenço FC, et al. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 2006; 26: 6209. (Pubitemid 44204538)
158. Mathivet T, Mazot P, Vigny M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase). Cell Signal 2007; 19: 2434.
159. Perez-Pinera P, Zhang W, Chang Y, Vega JA, Deuel TF. Anaplastic lymphoma kinase is activated through the pleiotrophin/ receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J Biol Chem 2007; 282: 28683. (Pubitemid 47606064)
160. Krueger NX, Saito H. A human transmembrane protein-tyrosine- phosphatase, PTP zeta, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases. Proc Natl Acad Sci U S A 1992; 89: 7417.
161. Levy JB, Canoll PD, Silvennoinen O, et al. The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system. J Biol Chem 1993; 268: 10573. (Pubitemid 23150247)
162. Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. 6B4 Proteoglycan/Phosphacan, an Extracellular Variant of Receptor-like Protein-tyrosine Phosphatase/RPTP, Binds Pleiotrophin/Heparin-binding Growth-associated Molecule (HB-GAM). J Biol Chem 1996; 271: 21446. (Pubitemid 26293009)
163. Garwood J, Heck N, Reichardt F, Faissner A. Phosphacan short isoform, a novel non-proteoglycan variant of phosphacan/receptor protein tyrosine phosphatase-beta, interacts with neuronal receptors and promotes neurite outgrowth. J Biol Chem 2003; 278: 24164. (Pubitemid 36830252)
164. Maurel P, Rauch U, Flad M, Margolis RK, Margolis RU. Phosphacan, a chondroitin sulfate proteoglycan of brain that interacts with neurons and neural cell-adhesion molecules, is an extracellular variant of a receptor-type protein tyrosine phosphatase. Proc Natl Acad Sci U S A 1994; 91: 2512.
165. Maeda N, He J, Yajima Y, Mikami T, Sugahara K, Yabe T. Heterogeneity of the Chondroitin Sulfate Portion of Phosphacan/ 6B4 Proteoglycan Regulates Its Binding Affinity for Pleiotrophin/ Heparin Binding Growth-associated Molecule. J Biol Chem 2003; 278: 35805. (Pubitemid 37102358)
166. Chow JP, Fujikawa A, Shimizu H, Suzuki R, Noda M. Metalloproteinase and gamma-secretase mediated cleavage of protein tyrosine phosphatase receptor type Z. J Biol Chem 2008; 283: 30879.
167. Chow JP, Fujikawa A, Shimizu H, Noda M. Plasmin-mediated processing of protein tyrosine phosphatase receptor type Z in the mouse brain. Neurosci Lett 2008; 442: 208.
168. Meng K, Rodriguez-Pena A, Dimitrov T, et al. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc Natl Acad Sci U S A 2000; 97: 2603. (Pubitemid 30159217)
169. Pariser H, Herradon G, Ezquerra L, Perez-Pinera P, Deuel TF. Pleiotrophin regulates serine phosphorylation and the cellular distribution of beta-adducin through activation of protein kinase C. Proc Natl Acad Sci U S A 2005; 102: 12407. (Pubitemid 41266372)
170. Pariser H, Ezquerra L, Herradon G, Perez-Pinera P, Deuel TF. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem Biophys Res Commun 2005; 332: 664. (Pubitemid 40745166)
171. Vacherot F, Delbe J, Heroult M, Barritault D, Fernig DG, Courty J. Glycosaminoglycans differentially bind HARP and modulate its biological activity. J Biol Chem 1999; 274: 7741. (Pubitemid 129518161)
172. Bernard-Pierrot I, Heroult M, Lemaitre G, Barritault D, Courty J, Milhiet PE. Glycosaminoglycans promote HARP/PTN dimerization. Biochem Biophys Res Commun 1999; 266: 437.
173. Maeda N, Fukazawa N, Hata T. The binding of chondroitin sulfate to pleiotrophin/heparin-binding growth-associated molecule is regulated by chain length and oversulfated structures. J Biol Chem 2006; 281: 4894. (Pubitemid 43847751)
174. Deepa SS, Umehara Y, Higashiyama S, Itoh N, Sugahara K. Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues. J Biol Chem 2002; 277: 43707. (Pubitemid 36157787)
175. Xingfeng B, Nishimura S, Mikami T, Yamada S, Itoh N, Sugahara K. Chondroitin sulfate/dermatan sulfate hybrid chains from embryonic pig brain, which contain a higher proportion of liduronic acid than those from adult pig brain, exhibit neuritogenic and growth factor binding activities. J Biol Chem 2004; 279: 9765. (Pubitemid 38372574)
176. Bao X, Mikami T, Yamada S, Faissner A, Muramatsu T, Sugahara K. Heparin-binding growth factor, pleiotrophin, mediates neuritogenic activity of embryonic pig brain-derived chondroitin sulfate/dermatan sulfate hybrid chains. J Biol Chem 2005; 280: 9180. (Pubitemid 40409608)
177. Li F, Shetty AK, Sugahara K. Neuritogenic activity of chondroitin/ dermatan sulfate hybrid chains of embryonic pig brain and their mimicry from shark liver. Involvement of the pleiotrophin and hepatocyte growth factor signaling pathways. J Biol Chem 2007; 282: 2956. (Pubitemid 47084329)
178. Malavaki C, Mizumoto S, Karamanos N, Sugahara K. Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect Tissue Res 2008; 49: 133.
179. Zou K, Muramatsu H, Ikematsu S, et al. A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican. Eur J Biochem 2000; 267: 4046. (Pubitemid 30436097)
180. Umehara Y, Yamada S, Nishimura S, Shioi J, Robakis NK, Sugahara K. Chondroitin sulfate of appican, the proteoglycan form of amyloid precursor protein, produced by C6 glioma cells interacts with heparin-binding neuroregulatory factors. FEBS Lett 2004; 557: 233. (Pubitemid 38115901)
181. Bao X, Muramatsu T, Sugahara K. Demonstration of the pleiotrophin-binding oligosaccharide sequences isolated from chondroitin sulfate/dermatan sulfate hybrid chains of embryonic pig brains. J Biol Chem 2005; 280: 35318. (Pubitemid 41532720)
182. Take M, Tsutsui J, Obama M, et al. Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). J Biochem 1994; 116: 1063. (Pubitemid 24354656)
183. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003; 163: 871. (Pubitemid 37517893)
184. Destouches D, Khoury D, Hamma-Kourbali Y, et al. Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS ONE 2008; 3: e2518.
185. Joo EJ, ten Dam GB, van Kuppevelt TH, Toida T, Linhardt RJ, Kim YS. Nucleolin: acharan sulfate-binding protein on the surface of cancer cells. Glycobiology 2005; 15: 1.
186. Said EA, Courty J, Svab J, Delbe J, Krust B, Hovanessian AG. Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin. FEBS J 2005; 272: 4646. (Pubitemid 41366988)